TrialThe oncologist2023

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.

Luis Meza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.